Product Images Sacubitril And Valsartan

This text provides information about a medication containing 24 mg of sacubitril and 26 mg of valsartan. It includes instructions on storage conditions, keeping the drugs out of reach of children, and dispensing in a tight container with a child-resistant closure. The batch and expiration details are mentioned for serialization purposes. It also mentions the manufacturer and distributor details of the tablets. Dosage guidance is advised to be in accordance with the prescribing information provided. The tablets come in a pack of 500 and are intended for prescription use only.*

Each film-coated tablet contains 49 mg of sacubitril and 51 mg of valsartan. Keep this and all drugs out of the reach of children. Store at 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F). Protect from moisture. Dispense in a tight container with a child-resistant closure. It is recommended to refer to the prescribing information for the usual dosage. Manufactured by TORRENT PHARMACEUTICALS LTD, Bharuch-392130, INDIA. Manufactured for TORRENT PHARMA INC, Basking Ridge, NJ 07920. This product comes in a package of 500 tablets, with the NDC 13668-635-05. The unvarnished area is intended for imprinting of batch and expiration date, as well as serialization information.*

This text provides information about a medicine containing sacubitril and valsartan in film-coated tablet form. It includes details on dosage, storage conditions, manufacturer information, and batch details such as NDC number. The text also emphasizes keeping the medication out of reach of children, storing it at specific temperatures, and protecting it from moisture. It also mentions a child-resistant closure and includes the manufacturer's location in India and the License Number.*

This is a description of the time to the first occurrence of cardiovascular death or heart failure hospitalizations in the PARADIGM-HF study. The statistical significance was shown by p<0.0001, with hazard ratio (HR) of 0.80 (95% CI: 0.73, 0.87). The study involved the use of sacubitril and valsartan. The graph displays the time since randomization (in days) on the x-axis and the occurrence of events on the y-axis.*

This is a statistical analysis of the time to occurrence of cardiovascular death in the PARADIGM-HF study. The Kaplan-Meier estimate of the cumulative failure rate and hazard ratio (HR) are provided. The graph shows the time since randomization in days and the number at risk in each group. The study compares the outcomes of patients receiving Valsartan versus Enalapril.*

This data appears to show the time to the first occurrence of heart failure hospitalizations in the PARADIGM-HF study, comparing Enalapril and Sacubitril/Valsartan. It includes a hazard ratio (HR) with a confidence interval of 95%. The graph ranges from 0 to 1260 days since randomization, displaying cumulative failure rates over time.*

This is not readable.*

This text provides information on hazard ratios for different medications in studies such as PARADIGM-HF and PARAGON-HF. It also includes left ventricular ejection fraction percentages at screening. This data could be used to evaluate the effectiveness of sacubitril and valsartan compared to enalapril and valsartan in treating heart failure.*